argenx SE (ARGX)Healthcare | Biotechnology | Amsterdam, Netherlands | NasdaqGS
819.14 USD
-27.13
(-3.206%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 819.14 |
Hot Take ↕ | Oct. 10, 2026, 7:26 a.m. EDT
The long-term outlook remains exceptionally strong, driven by a flawless eight-year price trajectory and robust fundamentals including 59% revenue growth and a fortress balance sheet with minimal debt. The business is generating substantial cash and delivering superior returns on equity, justifying a premium valuation despite the high price-to-sales multiple. However, the short-term chart is currently lagging, trading below both the 50-day and 200-day moving averages, which creates a technical headwind. Options activity confirms this tension, with traders placing protective hedges near current prices while maintaining bullish exposure further out. There is no income component to the investment, relying entirely on capital appreciation. While the statistical forecast offers only a weak lean upward, the fundamental quality and recent positive news regarding product efficacy and acquisitions suggest the current weakness may be a temporary consolidation before the next leg up. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.123408 |
| AutoTheta | 0.126381 |
| AutoARIMA | 0.127010 |
| MSTL | 0.128114 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 0.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.024 |
| Excess Kurtosis | -0.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.558 |
| Revenue per Share | 3.43648 |
| Market Cap | 51,512,496,128 |
| Trailing P/E | 31.22 |
| Forward P/E | 23.02 |
| Beta | -0.04 |
| Profit Margins | 32.27% |
| Website | https://argenx.com |
As of Oct. 10, 2026, 7:26 a.m. EDT: Speculators are positioning defensively around current levels with notable put volume at the 900 strike, suggesting a hedge against a near-term pullback. However, call open interest builds significantly at higher strikes (1160, 1240), indicating a bullish thesis for the medium term. Implied volatility is elevated across expirations, reflecting uncertainty around the upcoming catalysts and acquisition news.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.035693288 |
| Address1 | Laarderhoogtweg 25 |
| All Time High | 1,072.75 |
| All Time Low | 17.33 |
| Ask | 977.32 |
| Ask Size | 1 |
| Average Analyst Rating | 1.5 - Buy |
| Average Daily Volume10 Day | 585,900 |
| Average Daily Volume3 Month | 329,117 |
| Average Volume | 329,117 |
| Average Volume10Days | 585,900 |
| Beta | -0.043 |
| Bid | 850.33 |
| Bid Size | 1 |
| Book Value | 5.3836 |
| City | Amsterdam |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 819.14 |
| Current Ratio | 5.123 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 843.61 |
| Day Low | 813.05 |
| Debt To Equity | 0.558 |
| Display Name | argenx |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,792,699,200 |
| Earnings Call Timestamp Start | 1,792,699,200 |
| Earnings Growth | 0.952 |
| Earnings Quarterly Growth | 0.922 |
| Earnings Timestamp | 1,792,672,200 |
| Earnings Timestamp End | 1,792,672,200 |
| Earnings Timestamp Start | 1,792,672,200 |
| Ebitda | 1,612,902,016 |
| Ebitda Margins | 0.30344 |
| Enterprise To Ebitda | 790.839 |
| Enterprise To Revenue | 239.969 |
| Enterprise Value | 1,275,545,911,296 |
| Eps Current Year | 18.6775 |
| Eps Forward | 35.59 |
| Eps Trailing Twelve Months | 26.24 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 952.865 |
| Fifty Day Average Change | -133.72498 |
| Fifty Day Average Change Percent | -0.1403399 |
| Fifty Two Week Change Percent | -3.5693288 |
| Fifty Two Week High | 1,072.75 |
| Fifty Two Week High Change | -253.60999 |
| Fifty Two Week High Change Percent | -0.23641108 |
| Fifty Two Week Low | 661.85 |
| Fifty Two Week Low Change | 157.29004 |
| Fifty Two Week Low Change Percent | 0.23765211 |
| Fifty Two Week Range | 661.85 - 1072.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,495,114,200,000 |
| Float Shares | 1,560,805,848 |
| Forward Eps | 35.59 |
| Forward P E | 23.016016 |
| Free Cashflow | 761,769,024 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,863 |
| Fullday Change | -27.130005 |
| Fullday Change Percent | -3.2058332 |
| Fullday Price | 819.14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.59067 |
| Gross Profits | 3,139,672,064 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.46131 |
| Implied Shares Outstanding | 62,886,074 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. |
| Long Name | argenx SE |
| Market | us_market |
| Market Cap | 51,512,496,128 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_62120637 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 1,715,035,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 59,856,699,130 |
| Number Of Analyst Opinions | 23 |
| Open | 842.8 |
| Operating Cashflow | 974,192,000 |
| Operating Margins | 0.31992 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.01 |
| Phone | 31 10 703 8441 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 819.14 |
| Post Market Time | 1,792,180,935 |
| Previous Close | 846.27 |
| Price Eps Current Year | 43.857048 |
| Price Hint | 2 |
| Price To Book | 152.1547 |
| Price To Sales Trailing12 Months | 9.691054 |
| Profit Margins | 0.32265 |
| Quick Ratio | 4.524 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.52 |
| Region | US |
| Regular Market Change | -27.13 |
| Regular Market Change Percent | -3.20583 |
| Regular Market Day High | 843.61 |
| Regular Market Day Low | 813.05 |
| Regular Market Day Range | 813.05 - 843.61 |
| Regular Market Open | 842.8 |
| Regular Market Previous Close | 846.27 |
| Regular Market Price | 819.14 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 388,982 |
| Return On Assets | 0.11635 |
| Return On Equity | 0.23635 |
| Revenue Growth | 0.593 |
| Revenue Per Share | 3.43648 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 62,886,074 |
| Shares Percent Shares Out | 0.0216 |
| Shares Short | 1,352,184 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,259,349 |
| Short Name | argenx SE |
| Short Percent Of Float | 0.0216 |
| Short Ratio | 5.51 |
| Source Interval | 15 |
| Symbol | ARGX |
| Target High Price | 1,356.0 |
| Target Low Price | 823.0 |
| Target Mean Price | 1,152.9131 |
| Target Median Price | 1,140.0 |
| Total Cash | 5,184,000,000 |
| Total Cash Per Share | 3.316 |
| Total Debt | 47,000,000 |
| Total Revenue | 5,315,468,800 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 26.24 |
| Trailing P E | 31.217226 |
| Trailing Peg Ratio | 1.1521 |
| Triggerable | 1 |
| Two Hundred Day Average | 851.37744 |
| Two Hundred Day Average Change | -32.237427 |
| Two Hundred Day Average Change Percent | -0.037865024 |
| Type Disp | Equity |
| Volume | 388,982 |
| Website | https://argenx.com |
| Zip | 1,101 EB |